Bioverativ Inc (NASDAQ:BIVV) Director Louis J. Paglia acquired 2,000 shares of the company’s stock in a transaction on Monday, August 7th. The stock was acquired at an average cost of $59.70 per share, for a total transaction of $119,400.00. Following the completion of the acquisition, the director now owns 5,056 shares of the company’s stock, valued at approximately $301,843.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bioverativ Inc (BIVV) traded down 2.13% during trading on Tuesday, hitting $59.39. The stock had a trading volume of 1,049,869 shares. The stock’s 50 day moving average price is $61.33 and its 200 day moving average price is $55.37. The firm has a market cap of $6.44 billion and a P/E ratio of 14.11. Bioverativ Inc has a 12-month low of $41.88 and a 12-month high of $64.41.

Bioverativ (NASDAQ:BIVV) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported $0.88 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.17. The firm had revenue of $289.10 million during the quarter, compared to analyst estimates of $269 million. The business’s revenue was up 37.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.59 EPS. On average, analysts anticipate that Bioverativ Inc will post $2.89 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Insider Buying: Bioverativ Inc (BIVV) Director Buys 2,000 Shares of Stock” was published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at

Several analysts have commented on BIVV shares. Zacks Investment Research raised Bioverativ from a “hold” rating to a “strong-buy” rating and set a $73.00 price objective on the stock in a report on Tuesday, July 25th. Cowen and Company raised Bioverativ from a “market perform” rating to an “outperform” rating in a report on Monday, July 10th. Jefferies Group LLC reissued a “buy” rating on shares of Bioverativ in a report on Friday, June 30th. Deutsche Bank AG started coverage on Bioverativ in a report on Friday, June 23rd. They issued a “hold” rating and a $65.00 price objective on the stock. Finally, Credit Suisse Group raised their price objective on Bioverativ from $45.00 to $47.00 and gave the company an “underperform” rating in a report on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $59.31.

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with's FREE daily email newsletter.